stockrowWhat it does
BridgeBio Pharma is a commercial-stage biopharmaceutical company that discovers, develops and sells medicines for patients with genetic diseases. Founded in 2015, it is led by chief executive Neil Kumar, Ph.D.
Its largest commercial product is acoramidis, sold as Attruby in the United States for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM. In this progressive heart disease, an unstable protein can form deposits in the heart. Attruby is an oral medicine designed to stabilize that protein and reduce cardiovascular deaths and hospitalizations.
Outside the United States, the same medicine is sold as Beyonttra. Bayer commercializes it in Europe, Alexion commercializes it in Japan, and BridgeBio sells it directly in certain other international markets. BridgeBio also developed Nulibry for a rare metabolic disease; Sentynl Therapeutics now owns the global rights and handles its development, manufacturing and commercialization.
BridgeBio runs multiple development programs through a hub-and-spoke model. Dedicated teams lead individual programs, while a central organization provides business, finance, clinical, regulatory and commercial services. Its late-stage candidates include infigratinib for achondroplasia, a genetic condition affecting bone growth; BBP-418 for a form of muscular dystrophy; and encaleret for a rare condition affecting calcium regulation. These candidates require regulatory approval before they can be marketed for those uses.
How it makes money
BridgeBio earns product revenue from U.S. sales of Attruby and receives licensing revenue and royalties from partners selling acoramidis as Beyonttra abroad. Product and royalty revenue can recur with sales, while licensing revenue can include one-time payments tied to regulatory or sales milestones. The company’s material revenue comes from acoramidis; its other late-stage candidates have not yet been approved for their proposed uses.
In 2025, Attruby generated $362.4 million in U.S. net product revenue. Beyonttra contributed $105.0 million in license and services revenue following European and Japanese approvals, plus $11.4 million in royalty revenue primarily earned on sales in those markets. Under its European license, BridgeBio can receive sales milestones and tiered royalties beginning in the low-thirties percent of Bayer’s net sales, subject to contractual reductions. Its Japanese agreement provides royalties in the low-teens based on net sales.
Total revenue in the third quarter of 2026 was $353.2 million, including $253.2 million of U.S. Attruby net product revenue and $75 million in license revenue from a one-time Bayer sales milestone. Royalty revenue for the quarter was $20.5 million, primarily from Beyonttra sales in Europe and Japan.
BridgeBio has sold certain rights to European acoramidis royalty payments for $300.0 million. Those purchaser rights are subject to contractual caps. BridgeBio also uses financing, including convertible notes and debt, to fund its operations. It offers eligible patients co-pay assistance, a patient assistance program and a free trial for Attruby; its revenue depends on the resulting net product sales rather than the listed price alone.
Customers and how it sells
Attruby is prescribed for adults with ATTR-CM. BridgeBio’s U.S. sales force calls on treatment centers and community cardiologists, while the medicine reaches patients through a limited network of specialty pharmacies, specialty distributors and third-party logistics providers. It can be dispensed directly to patients or through approved hospital pharmacies.
As of February 20, 2026, Attruby had received 7,804 unique patient prescriptions and had been prescribed by 1,856 healthcare professionals in the United States. BridgeBio said approximately 2,900 physicians had tried Attruby by the third quarter of 2026, mostly cardiologists at academic medical centers or high-volume heart-failure practices. The company also said more than 60% of prescribers had yet to try it.
Customers are concentrated: in fiscal 2025, Customer B represented 19.8% of revenue, Customer A 18.5%, and Bayer 14.4%. BridgeBio licenses Beyonttra to Bayer in Europe and Alexion in Japan, while commercializing it directly in certain other international markets. Bayer’s territory includes EU member states, the United Kingdom, Switzerland and Turkey.
Suppliers and costs
BridgeBio does not own or operate manufacturing facilities. It relies on contract manufacturers for raw materials, drug substance, finished drug products and packaging for commercial medicines, preclinical research and clinical trials. It has long-term manufacturing agreements to support Attruby in the United States and Beyonttra in certain international markets. Employees and outside consultants oversee those manufacturer relationships.
Research and development, clinical trials, commercial operations and launch preparations are costs. The company also uses contract research organizations and other vendors for trials and preclinical work. Advancing programs through later-stage trials without a partner requires substantial spending.
Total operating expenses were $344.4 million in the third quarter of 2026, reflecting continued investment in Attruby and preparations for potential launches. BridgeBio expects operating expenses to increase in the fourth quarter as launch-related spending catches up. It had 839 employees in fiscal 2025.
- Revenue$502.1M
- Cost of revenue−$21.0M
- Research and development−$452.0M
- Selling, general and administrative−$531.2M
- Other operating costs−$21.3M
- Operating income−$523.4M
Competitive position
BridgeBio competes with pharmaceutical and biotechnology companies developing treatments for the same diseases. Competition depends on clinical performance, regulatory approval, intellectual property, pricing, reimbursement and commercial execution. Some competitors may have greater financial, manufacturing and commercial resources.
Attruby competes in ATTR-CM. BridgeBio said it was in second place for new patient starts in the third quarter of 2026, while noting that it was waiting for Pfizer’s results to assess its share trajectory. It was reported on 1 November 2026 that competitive pressure from Pfizer or Alnylam could intensify. In achondroplasia, approved injectable treatments are available; it was reported on 30 October 2026 that BridgeBio viewed an Ascendis Pharma citizen petition as an attempt to delay a competing infigratinib launch.
Attruby’s U.S. label specifies near-complete stabilization of the transthyretin protein. BridgeBio also has a U.S. sales organization and international partners for acoramidis. Its infigratinib candidate is administered orally but has not yet been approved for achondroplasia.
Our reading: Attruby’s label and clinical data provide a product-based distinction, but their commercial protection is constrained by competing therapies and reimbursement decisions. Our reading: BridgeBio’s sales network and partners support distribution, although larger competitors’ resources can limit that advantage. Our reading: The development portfolio could add differentiated products, but it does not yet provide the protection of approved, marketed therapies.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Pfizer | ATTR-CM treatments | High |
| Alnylam | Rare-disease therapies | Medium |
| Ascendis Pharma | Potential competition around infigratinib’s launch | Medium |
Growth opportunities
BridgeBio is pursuing growth from wider use of Attruby, partner sales of Beyonttra and potential launches of its late-stage candidates. It estimates approximately 240,000 ATTR-CM patients in the United States, within a global population of around 500,000. The company believes diagnosis will increase as awareness and use of non-invasive diagnostic techniques grow.
In the third quarter of 2026, BridgeBio reported continued Attruby growth and said it planned to reach more prescribers, including lower-volume physicians. It also received a one-time Bayer sales milestone for Beyonttra. The company is studying acoramidis further in ASCEND-ATTR, which examines cardiac structure, function and amyloid burden.
Three candidates were under U.S. regulatory review as of the third-quarter update. BridgeBio identified a November 27 action date for BBP-418 in limb-girdle muscular dystrophy type 2I. The FDA granted priority review to infigratinib for achondroplasia, with an action date of February 4, 2027, and to encaleret for ADH1, with an action date of May 8, 2027. BridgeBio also submitted European marketing applications for infigratinib and encaleret. Approval and launch are not assured.
Beyond ADH1, BridgeBio has begun a registrational Phase 3 study of encaleret in chronic hypoparathyroidism. It estimates that condition affects approximately 200,000 patients in the United States and European Union. The company has also nominated BBP-717, an antibody depleter for ATTR-CM, as a development candidate and plans an investigational new drug submission in 2027.
- $69.7MFY2021
- $77.6MFY2022
- $9.3MFY2023
- $221.9MFY2024
- $502.1MFY2025
Structural risks
- Commercial concentration: BridgeBio’s business is substantially dependent on the commercial success of Attruby and Beyonttra. Market acceptance depends on factors including clinical performance, pricing, reimbursement, patient access and competing products.
- Development and approval: Clinical trials can be delayed or produce negative or inconclusive results. The company cannot be certain that regulators will approve its candidates on a timely basis, or at all.
- Funding and losses: BridgeBio incurred a net loss of $732.9 million in 2025 and expects operating and net losses for at least the next several years. Changes in its plans or commercial timing could require additional funding sooner, and financing may not be available on acceptable terms.
- Manufacturing and distribution: BridgeBio relies on outside manufacturers and distribution providers. Supply-chain or distribution disruptions could delay or prevent a product launch or continued commercialization.
- Healthcare regulation: Marketing, distribution and relationships with healthcare providers and payers are subject to fraud-and-abuse and other laws. Violations could result in penalties, exclusion from government-funded healthcare programs or changes to operations.
Bottom line
Our reading
Our reading: BridgeBio combines a commercial heart-disease medicine with a portfolio of genetic-disease candidates, but current material revenue rests on acoramidis. [item7] Its next phase depends on converting regulatory reviews into approvals and launches while continuing to fund development and commercial operations. [call_prepared] The partner network extends its geographic reach, while reliance on outside manufacturers, ongoing losses and financing obligations remain material exposures. [item1] [item7]